INTELENCE 100 MG
ETRAVIRINE : 100 MG · DIN 02306778 · JANSSEN INC
Health Canada status: MARKETED
What is INTELENCE?
INTELENCE 100 MG contains ETRAVIRINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02306778, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Mar-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INTELENCE used for?
Treatment of HIV-1 in treatment-experienced adults and pediatric patients (6 to <18 years, >=30 kg) with resistance to multiple agents including NNRTIs, in combination with other antiretrovirals.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02306778 |
|---|---|
| Brand name | INTELENCE |
| Generic / active ingredient | ETRAVIRINE : 100 MG |
| Manufacturer | JANSSEN INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AG04 ETRAVIRINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Mar-2008 |
How is it administered?
Adults/Pediatrics (>=30kg): 200 mg twice daily following a meal. Tablets should be swallowed whole or dispersed in water if unable to swallow. Use with other antiretrovirals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (Section 11 header present but content missing), though typically 15-30°C for this form.
How is it supplied?
100 mg tablets: bottles of 120. 200 mg tablets: bottles of 60. Each bottle contains 3 desiccant pouches.
Contraindications
Co-administration with ombitasvir/paritaprevir/ritonavir and drugs containing dasabuvir; hypersensitivity to etravirine or any ingredient in the formulation.
Warnings and precautions
Severe/fatal skin reactions (SJS, TEN, DRESS) reported; discontinue immediately if symptoms occur. Risk of immune reconstitution inflammatory syndrome, pancreatitis, and hepatic effects.
What can be used instead?
Other Canadian products sharing ATC code J05AG04 ETRAVIRINE. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INTELENCE | 200 MG | TABLET | JANSSEN INC | MARKETED | DIN 02375931 |
| INTELENCE | 25 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 02396750 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.